 William Mustain
Concepts (184)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vestibule, Labyrinth | 6 | 2016 | 16 | 0.640 |
Why?
| | Vestibular Evoked Myogenic Potentials | 4 | 2022 | 5 | 0.540 |
Why?
| | Acoustic Stimulation | 6 | 2022 | 97 | 0.480 |
Why?
| | Colitis | 1 | 2013 | 51 | 0.440 |
Why?
| | Adipose Tissue | 1 | 2013 | 187 | 0.410 |
Why?
| | Gene Expression | 1 | 2013 | 609 | 0.380 |
Why?
| | Cell Physiological Phenomena | 1 | 2011 | 3 | 0.380 |
Why?
| | Disease | 1 | 2011 | 25 | 0.370 |
Why?
| | Neurotensin | 1 | 2011 | 16 | 0.370 |
Why?
| | Cytokines | 1 | 2013 | 613 | 0.370 |
Why?
| | Colorectal Neoplasms | 4 | 2015 | 236 | 0.360 |
Why?
| | Otolithic Membrane | 4 | 2022 | 4 | 0.300 |
Why?
| | Neck Muscles | 2 | 2016 | 5 | 0.230 |
Why?
| | Signal Transduction | 4 | 2014 | 1622 | 0.210 |
Why?
| | Animals | 16 | 2022 | 13246 | 0.200 |
Why?
| | Abdominal Muscles | 1 | 2021 | 14 | 0.190 |
Why?
| | Neuromuscular Blockade | 1 | 2021 | 11 | 0.190 |
Why?
| | Anesthesia, Conduction | 1 | 2021 | 17 | 0.190 |
Why?
| | Oculomotor Muscles | 2 | 2010 | 23 | 0.180 |
Why?
| | Disease Models, Animal | 5 | 2014 | 1458 | 0.170 |
Why?
| | Length of Stay | 1 | 2021 | 621 | 0.150 |
Why?
| | Neurons, Afferent | 2 | 2016 | 30 | 0.150 |
Why?
| | Rats, Sprague-Dawley | 7 | 2022 | 1586 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 66 | 0.140 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2014 | 140 | 0.130 |
Why?
| | Hearing Loss, Noise-Induced | 1 | 2016 | 10 | 0.130 |
Why?
| | Noise | 1 | 2016 | 39 | 0.130 |
Why?
| | Muscle, Skeletal | 2 | 2012 | 765 | 0.130 |
Why?
| | Evoked Potentials, Auditory, Brain Stem | 2 | 2016 | 27 | 0.130 |
Why?
| | Reflex, Vestibulo-Ocular | 2 | 2016 | 6 | 0.130 |
Why?
| | Male | 17 | 2016 | 25399 | 0.130 |
Why?
| | Drug Carriers | 1 | 2015 | 71 | 0.120 |
Why?
| | RNA, Viral | 1 | 2015 | 126 | 0.120 |
Why?
| | Rats | 7 | 2022 | 3299 | 0.120 |
Why?
| | Dextran Sulfate | 1 | 2013 | 10 | 0.120 |
Why?
| | Surgical Flaps | 2 | 2006 | 120 | 0.120 |
Why?
| | Sound | 1 | 2013 | 11 | 0.120 |
Why?
| | Mesentery | 1 | 2013 | 32 | 0.110 |
Why?
| | Neuroendocrine Tumors | 1 | 2014 | 23 | 0.110 |
Why?
| | Portal Vein | 1 | 2013 | 24 | 0.110 |
Why?
| | Nanoparticles | 1 | 2015 | 152 | 0.110 |
Why?
| | Inflammation Mediators | 1 | 2013 | 113 | 0.110 |
Why?
| | Mice | 5 | 2015 | 5759 | 0.110 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2013 | 50 | 0.110 |
Why?
| | Cell Adhesion Molecules | 1 | 2013 | 89 | 0.110 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 162 | 0.110 |
Why?
| | Acute Disease | 1 | 2013 | 368 | 0.110 |
Why?
| | Genetic Therapy | 1 | 2013 | 114 | 0.100 |
Why?
| | Cell Line, Tumor | 5 | 2015 | 1416 | 0.100 |
Why?
| | Antigens, Neoplasm | 1 | 2013 | 152 | 0.100 |
Why?
| | Catheterization, Central Venous | 1 | 2013 | 84 | 0.100 |
Why?
| | Mastoid | 1 | 2012 | 51 | 0.100 |
Why?
| | Time Factors | 3 | 2013 | 2922 | 0.100 |
Why?
| | RNA Interference | 1 | 2012 | 179 | 0.100 |
Why?
| | Endothelial Cells | 1 | 2014 | 270 | 0.100 |
Why?
| | Colonic Neoplasms | 1 | 2013 | 159 | 0.100 |
Why?
| | Carcinoma | 1 | 2012 | 139 | 0.090 |
Why?
| | Disease Progression | 1 | 2013 | 831 | 0.090 |
Why?
| | Vestibular Nuclei | 1 | 2010 | 9 | 0.090 |
Why?
| | Central Nervous System Diseases | 1 | 2011 | 27 | 0.090 |
Why?
| | Bone Conduction | 1 | 2010 | 26 | 0.090 |
Why?
| | Auditory Threshold | 1 | 2010 | 49 | 0.090 |
Why?
| | Wakefulness | 1 | 2010 | 52 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2014 | 202 | 0.090 |
Why?
| | Evoked Potentials, Auditory | 1 | 2010 | 101 | 0.090 |
Why?
| | Central Nervous System | 1 | 2011 | 85 | 0.090 |
Why?
| | Neural Pathways | 1 | 2010 | 99 | 0.090 |
Why?
| | Electromyography | 1 | 2010 | 131 | 0.090 |
Why?
| | Gastrointestinal Diseases | 1 | 2011 | 126 | 0.090 |
Why?
| | Inflammation | 1 | 2013 | 604 | 0.080 |
Why?
| | Nystagmus, Optokinetic | 1 | 2008 | 1 | 0.080 |
Why?
| | Nystagmus, Physiologic | 1 | 2008 | 3 | 0.080 |
Why?
| | Fixation, Ocular | 1 | 2008 | 13 | 0.080 |
Why?
| | Models, Neurological | 1 | 2008 | 58 | 0.080 |
Why?
| | Bone Substitutes | 1 | 2007 | 11 | 0.070 |
Why?
| | Humans | 12 | 2021 | 50208 | 0.070 |
Why?
| | Peripheral Nerve Injuries | 1 | 2006 | 24 | 0.070 |
Why?
| | Semicircular Canals | 2 | 2016 | 13 | 0.060 |
Why?
| | Rectus Abdominis | 1 | 2004 | 7 | 0.060 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2004 | 15 | 0.060 |
Why?
| | Reference Values | 3 | 2010 | 310 | 0.060 |
Why?
| | Vestibular Nerve | 2 | 2016 | 6 | 0.060 |
Why?
| | Adult | 6 | 2021 | 13324 | 0.060 |
Why?
| | Bone and Bones | 1 | 2007 | 475 | 0.050 |
Why?
| | Gene Knockdown Techniques | 2 | 2014 | 106 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2014 | 212 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2013 | 215 | 0.050 |
Why?
| | Acoustics | 1 | 2022 | 33 | 0.050 |
Why?
| | Colorectal Surgery | 1 | 2021 | 17 | 0.050 |
Why?
| | Hospitals, Teaching | 1 | 2021 | 53 | 0.050 |
Why?
| | Electrodes | 2 | 2010 | 36 | 0.050 |
Why?
| | Neoplasms | 1 | 2011 | 1249 | 0.050 |
Why?
| | Narcotics | 1 | 2021 | 111 | 0.050 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2021 | 117 | 0.040 |
Why?
| | Models, Animal | 2 | 2013 | 232 | 0.040 |
Why?
| | Liver Neoplasms | 2 | 2015 | 328 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2014 | 1013 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2021 | 1126 | 0.040 |
Why?
| | Apoptosis | 2 | 2014 | 1112 | 0.040 |
Why?
| | Hospitalization | 1 | 2021 | 655 | 0.030 |
Why?
| | Rats, Long-Evans | 1 | 2016 | 26 | 0.030 |
Why?
| | Rotation | 1 | 2016 | 45 | 0.030 |
Why?
| | Female | 5 | 2016 | 26635 | 0.030 |
Why?
| | Posture | 1 | 2016 | 61 | 0.030 |
Why?
| | Bacillus Phages | 1 | 2015 | 2 | 0.030 |
Why?
| | RNA Stability | 1 | 2015 | 24 | 0.030 |
Why?
| | Folate Receptor 1 | 1 | 2015 | 24 | 0.030 |
Why?
| | Chick Embryo | 1 | 2014 | 82 | 0.030 |
Why?
| | Diphenylamine | 1 | 2014 | 5 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 32 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 121 | 0.030 |
Why?
| | Aminopyridines | 1 | 2014 | 15 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2015 | 227 | 0.030 |
Why?
| | Benzamides | 1 | 2014 | 51 | 0.030 |
Why?
| | Quinolines | 1 | 2014 | 41 | 0.030 |
Why?
| | Polystyrenes | 1 | 2013 | 4 | 0.030 |
Why?
| | Base Sequence | 1 | 2015 | 644 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2014 | 89 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 151 | 0.030 |
Why?
| | Microspheres | 1 | 2013 | 26 | 0.030 |
Why?
| | Tumor Burden | 1 | 2014 | 131 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 85 | 0.030 |
Why?
| | Morpholines | 1 | 2014 | 70 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2014 | 155 | 0.030 |
Why?
| | Action Potentials | 1 | 2013 | 132 | 0.030 |
Why?
| | Saccule and Utricle | 1 | 2012 | 2 | 0.030 |
Why?
| | Reaction Time | 1 | 2013 | 216 | 0.030 |
Why?
| | Imidazoles | 1 | 2014 | 128 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 18 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2012 | 23 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2013 | 305 | 0.030 |
Why?
| | Fluorouracil | 1 | 2012 | 54 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2012 | 38 | 0.030 |
Why?
| | Paxillin | 1 | 2012 | 6 | 0.030 |
Why?
| | Oncogene Protein v-akt | 1 | 2012 | 10 | 0.030 |
Why?
| | ras Proteins | 1 | 2012 | 64 | 0.030 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2012 | 15 | 0.030 |
Why?
| | Lipogenesis | 1 | 2012 | 29 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 206 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2012 | 21 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2012 | 108 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 149 | 0.020 |
Why?
| | Afferent Pathways | 1 | 2011 | 12 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 198 | 0.020 |
Why?
| | Mice, Nude | 1 | 2012 | 254 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 166 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 534 | 0.020 |
Why?
| | Caloric Tests | 1 | 2010 | 2 | 0.020 |
Why?
| | Electrooculography | 1 | 2010 | 13 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2015 | 828 | 0.020 |
Why?
| | Eye Movements | 1 | 2010 | 26 | 0.020 |
Why?
| | Evoked Potentials, Visual | 1 | 2010 | 37 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 349 | 0.020 |
Why?
| | Macaca mulatta | 1 | 2010 | 93 | 0.020 |
Why?
| | Face | 1 | 2010 | 60 | 0.020 |
Why?
| | Neck | 1 | 2010 | 100 | 0.020 |
Why?
| | Models, Biological | 1 | 2012 | 723 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 979 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2021 | 6134 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2015 | 605 | 0.020 |
Why?
| | Dominance, Ocular | 1 | 2008 | 1 | 0.020 |
Why?
| | Vestibular Function Tests | 1 | 2008 | 8 | 0.020 |
Why?
| | Physical Stimulation | 1 | 2008 | 35 | 0.020 |
Why?
| | Liver | 1 | 2013 | 1116 | 0.020 |
Why?
| | Temperature | 1 | 2008 | 168 | 0.020 |
Why?
| | Bone Matrix | 1 | 2007 | 18 | 0.020 |
Why?
| | Neural Conduction | 1 | 2006 | 34 | 0.020 |
Why?
| | Young Adult | 1 | 2016 | 3981 | 0.020 |
Why?
| | Mutation | 1 | 2012 | 1294 | 0.020 |
Why?
| | Peripheral Nerves | 1 | 2006 | 49 | 0.020 |
Why?
| | Necrosis | 1 | 2006 | 178 | 0.020 |
Why?
| | Rabbits | 1 | 2006 | 374 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 1554 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2010 | 2190 | 0.020 |
Why?
| | Tissue Transplantation | 1 | 2004 | 8 | 0.010 |
Why?
| | Probability | 1 | 2004 | 164 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2004 | 181 | 0.010 |
Why?
| | Graft Survival | 1 | 2004 | 150 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 564 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 595 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 863 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 978 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2004 | 1108 | 0.010 |
Why?
| | Middle Aged | 1 | 2010 | 12206 | 0.010 |
Why?
|
|
Mustain's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|